Markets

Abbott's New Beta-CORRECT Data At ESMO Congress Demonstrates 30% Enhancement In Sensitivity For Colorectal Cancer Recurrence Within Two Years Of Surgery

Oct 23, 2026 · 09:17 AM ET· updated 2h ago

Abbott (NYSE:ABT) today announced new Beta-CORRECT data presented at the European Society for Medical Oncology (ESMO) Congress showing that the whole-genome sequencing (WGS)-based Oncodetect® molecular residual disease

Why It Matters

Abbott showed that a new cancer test finds recurrence 30% better. This hints the company's cancer detection tools are getting stronger and smarter.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ABT102.95

+0.44 (+0.43%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.